Deep sea as a source of novel-anticancer drugs: Update on discovery and preclinical/clinical evaluation in a systems medicine perspective

EXCLI Journal

Volumn 14, Issue , 2015, Pages 228-236

  Russo, Patrizia ^a   Del Bufalo, Alessandra ^a   Fini, Massimo ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Cancer; Clinical studies; Deep sea derived drugs; Network; Preclinical studies; Systems medicine; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARTHIAPEPTIDE A; PENIPACID A; PENIPACID B; PENIPACID C; PENIPACID D; PENIPACID E; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIPERAZINEDIONE; POMALIDOMIDE; PROTEASOME; PROTEIN P53; PYRAZIN 2(1H); SALINOSPORAMIDE A; SD 118 XANTHOCILLIN X; SORBICILLAMINE A; SORBICILLAMINE B; SORBICILLAMINE C; SORBICILLAMINE D; SORBICILLAMINE E; SUNGSANPIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACTINOBACTERIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BACILLUS PUMILUS; CANCER CELL; CANCER RECURRENCE; COGNITIVE DEFECT; DEEP SEA SPECIES; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HALLUCINATION; HEADACHE; HUMAN; LC50; LEUKEMIA; LYMPHOMA; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PENICILLIUM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SALINISPORA; SALINISPORA ARENICOLA; SALINISPORA PACIFICA; SALINISPORA TROPICA; STREPTOMYCES; VOMITING;

SALINISPORA;

EID: 84928253794     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2014-632     Document Type: Review

References (45)

1. Ahn KS, Sethi G, Chao TH, Neuteboom ST, Chatur-vedi MM, Palladino MA, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteo-clastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood. 2007;110:2286-95.
2. Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014; 38:1-9.
3. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29-46.
4. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 2013; 19:4025-38.
5. Cao B, Li J, Mao X. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des. 2013;19:3190-200.
6. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407–4.
7. Chen JY, Piquette-Miller M, Smith BP. Network medicine: finding the links to personalized therapy. Clin Pharmacol Therapeut. 2013;94:613-6.
8. Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene. 2014; Sep 15. [Epub ahead of print].
9. Einsele H. Bortezomib. Recent Res Cancer Res. 2014; 201:325-45.
10. Groll M, Potts BC. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr Top Med Chem. 2011;11:2850-78.
11. Guarducci M. Epigrafia greca. Istituto Poligrafico dello Stato, 1995.
12. Guo W, Peng J, Zhu T, Gu Q, Keyzers RA, Li D. Sorbicillamines A-E, nitrogen-containing sorbicilli-noids from the deep-sea-derived fungus Penicillium sp. F23-2. J Nat Prod. 2013;76:2106-12.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
15. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffen-burger DA, Yaffe MB. A systems model of signaling identifies a molecular basis set for cytokine induced apoptosis. Science. 2005; 310:1646-53.
16. Jara JH, Frank DD, Özdinler PH. Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1. Cell Biochem Biophys. 2013;67:45-53.
17. Jensen PR. Linking species concepts to natural product discovery in the post-genomic era. J Ind Microbiol Biotechnol. 2010; 37:219-24.
18. Jia W, Gao WY, Yan YQ, Wang J, Xu ZH, Zheng WJ, et al. The rediscovery of ancient Chinese herbal formulas. Phytother Res. 2004;18:681-6.
19. Kish-Trier E, Hill CP, Marguerat S, Schmidt A, Cod-lin S, Chen W, et al. Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cel. 2012;151:671-83.
20. Koslow T. The silent deep: the discovery, ecology and conservation of the deep sea. Chicago, IL: Univ. Chicago Press, 2007.
21. Laport MS, Santos OC, Muricy G. Marine sponges: potential sources of new antimicrobial drugs. Curr Pharm Biotechnol. 2009;10:86-105.
22. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev. 2012; 64:259-98.
23. Li CS, Li XM, Gao SS, Lu YH, Wang BG. Cytotoxic anthranilic acid derivatives from deep sea sediment-derived fungus Penicillium paneum SD-44. Mar Drugs. 2013;11:3068-76.
24. Li J, Mansmann UR. A molecular signaling map and its application. Cell Signal. 2014; 26:2834-42.
25. Manivasagan P, Venkatesan J, Sivakumar K, Kim SK. Marine actinobacterial metabolites: current status and future perspectives. Microbiol Res. 2013;168:311-32.
26. Marguerat S, Schmidt A, Codlin S, Chen W, Aeber-sold R, Bahler J. Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell. 2012;151:671-83.
27. Masoudi-Nejad A, Wang E. Cancer modeling and network biology: Accelerating toward personalized medicine. Semin Cancer Biol. 2015;30:1-3.
28. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor Marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30:2303-17.
29. Mincer TJ, Fenical W, Jensen, PR. Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus Salinispora. Appl Environ Microbiol. 2005;71:7019-28.
30. Moushumi Priya A, Jayachandran S. Induction of apoptosis and cell cycle arrest by Bis (2-ethylhexyl) phthalate produced by marine Bacillus pumilus MB 40. Chem Biol Interact. 2012;195:133-43.
31. Núñez-Pons L, Carbone M, Vázquez J, Rodríguez J, Nieto RM, Varela MM, et al. Natural Products from Antarctic Colonial Ascidians of the Genera Aplidium and Synoicum: Variability and Defensive Role. Mar Drugs. 2012;10:1741-64.
32. Pinchuk B, Johannes E, Gul S, Schlosser J, Schaechtele C, Totzke F, et al. Marine derived hama-canthins as lead for the development of novel PDG-FRβ protein kinase inhibitors. Mar Drugs. 2013;11: 3209-23.
33. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, et al. Marizomib, a protea-some inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011;11:254-84.
34. Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C, et al. Phase 1 clinical evaluation of twice-weekly Marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM) [(ASH Annual Meeting Abstracts) Abstract 302]. Blood. 2011;118:140-1.
35. Riddle JM. Folk tradition and folk medicine: recognition of drugs in classical antiquity. In: Scarboroough J (ed.): Folklore and folk medicine (pp 33-61). Madison: American Institute of the History of Pharmacy, 1987.
36. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103:1007-17.
37. Saetzler K, Sonnenschein C, Soto AM. Systems biology beyond networks: generating order from disorder through self-organization. Semin Cancer Biol. 2011; 21:165-74.
38. Settembre C, Ballabio A. Lysosome: regulator of lipid degradation pathways.Trends Cell Biol. 2014;24:743-50.
39. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des. 2014;20:23-36.
40. Udwary DW, Zeigler L, Asolkar RN, Singan V, Lapi-dus A, Fenical W, et al. Genome sequencing reveals complex secondary metabolome in the marine acti-nomycete Salinispora tropica. Proc Natl Acad Sci U S A. 2007;104:10376-81.
41. Um S, Kim YJ, Kwon H, Wen H, Kim SH, Kwon HC, et al. Sungsanpin, a lasso peptide from a deep-sea streptomycete. J Nat Prod. 2013;76:873-9.
42. Werner HM, Mills GB, Ram PT. Cancer systems biology: a peek into the future of patient care? Nat Rev Clin Oncol. 2014;11:167-76.
43. Zhang Q, Li S, Chen Y, Tian X, Zhang H, Zhang G, et al. New diketopiperazine derivatives from a deep-sea-derived Nocardiopsis alba SCSIO 03039. J Anti-biot (Tokyo). 2013;66:31-6.
44. Zhao Y, Chen H, Shang Z, Jiao B, Yuan B, Sun W, et al. SD118-xanthocillin X (1), a novel marine agent extracted from Penicillium commune, induces au-tophagy through the inhibition of the MEK/ERK pathway. Mar Drugs. 2012;10:1345-59.
45. Zhou X, Huang H, Chen Y, Tan J, Song Y, Zou J, et al. Marthiapeptide A, an anti-infective and cytotoxic polythiazole cyclopeptide from a 60 L scale fermentation of the deep sea-derived Marinactinospora ther-motolerans SCSIO 00652. J Nat Prod. 2012;75:2251-5.